CBD: from stigma to scientific recognition
The path of cannabidiol (CBD) to official recognition was long and thorny,
as this compound remained in the shadow of strict prohibitions and social
stereotypes for decades. Only through the persistent work of researchers was
humanity able to separate the plant's medical potential from its psychoactive
impact.
Early research and renewed interest
The pioneer of cannabidiol was Harvard graduate and chemist Roger Adams,
who isolated the substance back in 1940, predating the discovery of THC by
twenty-five years [1]. In the 1960s, scientists finally established the exact
chemical structure of the compound, which provided the first substantial
evidence of its therapeutic value, particularly its ability to significantly
alleviate the condition of patients with epilepsy [2]. Despite these
discoveries, the development of the field was artificially suppressed by
policies of criminalization and mass misinformation.
Positive changes in the legislative landscape began at the end of the last
century in the United States of America. A major milestone was 1996, when
California became the first state to legalize the use of cannabis for medical
purposes [3]. This created a precedent, thanks to which 36 other American
states and dozens of countries across various continents eventually allowed the
use of cannabinoids for patient treatment [4].
CBD against childhood epilepsy
A special place in the history of cannabidiol’s recognition is held by the
case of Charlotte Figi from Colorado, whose struggle for life changed the
world's attitude toward this substance. The girl, born in 2006, suffered from
catastrophic epileptic seizures from early childhood; by age five, their
frequency reached 300 episodes per day [5]. Due to constant seizures, Charlotte
lost the ability to speak, walk, and eat on her own, while traditional
medications proved not only ineffective but also toxic to her development.
Salvation came in the form of oil from a specific strain of hemp that had a
high concentration of CBD and contained almost no psychoactive THC. The very
first dose of the preparation stopped the seizures for an entire night, and
over time, their number was reduced to 2–3 cases per month. It was the
publicity of Charlotte's story that became the catalyst forcing the global
community to re-evaluate the safety and effectiveness of cannabidiol [6].
CBD receives recognition in 2018
Global recognition of CBD's status was finally solidified in 2018, when the
U.S. Food and Drug Administration (FDA) approved Epidiolex, a drug intended for
the treatment of complex forms of epilepsy in children [7]. That same year, the
World Health Organization released an official report confirming the safety of
the substance and its lack of potential for addiction or abuse [8].
In parallel, the World Anti-Doping Agency removed CBD from the list of
prohibited substances for athletes [9], and the U.S. legally permitted the
industrial cultivation of industrial hemp with a THC content below 0.3% [10]. A
logical conclusion to this stage was the UN decision in 2020 to remove products
with a THC content of less than 0.2% from strict international control [11].
Today, the cannabidiol market demonstrates impressive dynamics: in 2021,
its volume exceeded $3 billion, and analysts predict this figure could grow by
another $30 billion over the next five years [12].
The popularity of CBD products is driven by their wide range of
applications, as according to surveys:
- 40% of consumers use them to
reduce pain
- 20% — to combat anxiety
- 11% — to normalize sleep
- 8% — to relieve symptoms of
arthritis [13].
Thus, thanks to a scientific approach and real patient stories, cannabidiol has transformed from a stigmatized substance into a globally recognized remedy, returning hemp to its status as one of the most beneficial plants for humanity.
Resources:
https://norml.org/blog/2021/11/05/california-celebrates-25-years-of-medical-cannabis-access/
https://edition.cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/index.html
https://www.wada-ama.org/en/prohibited-list?page=0&q=thc&all=1
https://news.gallup.com/poll/263147/americans-say-cbd-products.aspx